Intra-arterial chemotherapy for the management of retinoblastoma four-year experience

Archives of Ophthalmology

Volumn 129, Issue 6, 2011, Pages 732-737

  Gobin, Y Pierre ^a   Dunkel, Ira J ^b   Marr, Brian P ^b   Brodie, Scott E ^b,c   Abramson, David H ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN HYDROGEN TARTRATE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; MELPHALAN; METHOTREXATE; TOPOTECAN;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTERY CATHETERIZATION; ARTERY OCCLUSION; ARTICLE; BRADYCARDIA; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILD; CLINICAL EFFECTIVENESS; CRYOTHERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; EYE EDEMA; FEMALE; FEMORAL ARTERY OCCLUSION; FEVER; HUMAN; HYPOTENSION; INFANT; INFLAMMATION; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OPHTHALMIC ARTERY; PATIENT SAFETY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; SCHOOL CHILD; SKIN DISCOLORATION; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRA-ARTERIAL; MALE; OPHTHALMIC ARTERY; PROSPECTIVE STUDIES; RETINA; RETINAL NEOPLASMS; RETINOBLASTOMA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958694863     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.5     Document Type: Article

References (32)

1. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24(6):828-848. (Pubitemid 39657479)
2. De Potter P. Current treatment of retinoblastoma. Curr Opin Ophthalmol. 2002;13(5):331-336.
3. Schefler AC, Abramson DH. Retinoblastoma: what is new in 2007-2008. Curr Opin Ophthalmol. 2008;19(6):526-534.
4. Reese AB, Hyman GA, Merriam GR Jr, Forrest AW, Kligerman MM. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954;53(4):505-513.
5. Mohri M. The technique of selective ophthalmic arterial infusion for conservative treatment of recurrent intraocular retinoblastoma [in Japanese]. Keio Igaku. 1993;70:679-687.
6. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9(2):69-73. (Pubitemid 38619319)
7. Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004;9(1):1-6. (Pubitemid 38470656)
8. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):1398- 1404.
9. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010;128(3):370-372.
10. Marr B, Gobin PY, Dunkel IJ, Brodie SE, Abramson DH. Spontaneously resolving periocular erythema and ciliary madarosis following intra-arterial chemotherapy for retinoblastoma. Middle East Afr J Ophthalmol. 2010;17(3):207-209.
11. Brodie SE, Pierre Gobin Y, Dunkel IJ, Kim JW, Abramson DH. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol. 2009;119(1):13-22.
12. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117(8):1623-1629.
13. Fledelius HC, Christensen AC. Reappraisal of the human ocular growth curve in fetal life, infancy, and early childhood. Br J Ophthalmol. 1996;80(10):918-921. (Pubitemid 26366563)
14. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122(9):1316-1323. (Pubitemid 39180851)
15. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121- 1128. (Pubitemid 23212278)
16. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-1267. (Pubitemid 27435614)
17. Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology. 2001;108(10):1868-1876. (Pubitemid 32905948)
18. Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ, Moll AC. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer. 2009;45(18):3245-3253.
19. Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1348-1356. (Pubitemid 26398720)
20. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18(1):12-17. (Pubitemid 30036331)
21. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol. 2000;18(15):2881-2887. (Pubitemid 30620076)
22. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133(5):657-664. (Pubitemid 34462014)
23. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol. 2002;120(12):1653-1658. (Pubitemid 36401799)
24. Lumbroso-Le Rouic L, Aerts I, Lévy-Gabriel C, et al. Conservative treatments of intraocular retinoblastoma. Ophthalmology. 2008;115(8):1405-1410.
25. Cohen VML, Kingston J, Hungerford JL. The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol. 2009;93(7):887-890.
26. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118(4):577-578. (Pubitemid 30203155)
27. Rizzuti AE, Dunkel IJ, Abramson DH. The adverse events of chemotherapy for retinoblastoma: what are they? do we know? Arch Ophthalmol. 2008;126(6):862-865. (Pubitemid 351831340)
28. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637-643.
29. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114(7):1378-1383. (Pubitemid 47008929)
30. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005;11(20):7569- 7578. (Pubitemid 41507720)
31. Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50(4):1492-1496.
32. Gobin YP, Cloughesy TF, Chow KL, et al. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology. 2001;218(3):724-732. (Pubitemid 32172554)